Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Burning Rock Partners with CStone for RET Companion Diagnostic

publication date: Jun 29, 2020

Burning Rock, a Guangzhou biotech, partnered with CStone Pharma to co-develop and commercialize companion diagnostics to detect RET alterations in cancer patients. Suzhou's CStone is developing pralsetinib in China for cancers caused by RET mutations, especially non-small cell lung cancer (NSCLC). Burning Rock specializes in Next-Gen Sequencing for precision oncology. The company has developed 32 tests for different cancer types and has labs in Beijing, Shanghai and Guangzhou. More details....

Stock Symbols: (NSDQ: BNR) (HK: 2616)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here